{
  "ticker": "PIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972359",
  "id": "02972359",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250724",
  "time": "1332",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250724/pdf/06m3d750x001ct.pdf",
  "summary": "### Key Material Information:  \n- **Product Performance**: Next-gen PromarkerD test shows:  \n  - 44x higher odds of kidney decline in high-risk patients vs. low-risk group  \n  - AUC 0.88 (excellent discrimination), negative predictive value up to 97.4%  \n  - Identifies 86% of at-risk patients missed by standard tests  \n- **Commercialization**: Now available for Type 2 diabetes patients in **Australia & USA**.  \n- **Market Potential**: Targets 537 million adults globally at risk of diabetic kidney disease (DKD).  \n\n*Note: No direct financial or capital markets impact disclosed (e.g., revenue forecasts, partnerships, or funding). Focus is on clinical validation and commercial readiness.*",
  "usage": {
    "prompt_tokens": 2550,
    "completion_tokens": 154,
    "total_tokens": 2704,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-24T04:53:41.922447"
}